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Osteoporosis is one of the most serious complications of
corticosteroid treatment. Loss of bone mineral density (BMD)
and fractures occur early in the course of corticosteroid
treatment, and thus early recognition of fracture risk and effec-
tive intervention based on evidence-based-medicine (EBM) are
needed. A study of meta-analysis representing the highest level
in a hierarchy of evidence showed that when the outcome
measure of interest was limited to changes in lumbar spine
BMD, bisphosphonates were the most effective of the agents
studied in comparison with no therapy or treatment with
calcium, and were also more efficacious than either vitamin
D or calcitonin; the efficacy of bisphosphonates was enhanced
when used in combination with vitamin D. Randomized
controlled trials (RCTs) representing the second level in a
hierarchy of evidence showed that bisphosphonates stabilized
BMD not only in the lumbar spine, but also in the hip, and
that parathyroid hormone (PTH) markedly increased lumbar
spine BMD. According to the EBM, bisphosphonates and
possibly PTH are suggested to be the most efficacious for
preserving BMD. The efficacy of these agents in reducing the
incidence of vertebral fractures in patients exposed to cortico-
steroids remains to be established in meta-analysis studies,
although some RCTs have demonstrated the anti-fracture
effects of etidronate, alendronate, and risedronate in the spine.
Further RCTs of fracture prevention conducted on a large
number of patients and their meta-analysis are needed to
confirm the efficacy of bisphosphonates, PTH, or other agents
in preventing vertebral and nonvertebral fractures.
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INTRODUCTION
Corticosteroids are widely used for the treat-
ment of a variety of diseases such as asthma, in-
flammatory and allergic disorders, and other
diseases affecting the gastrointestinal tract and
central nervous system. Although corticosteroid
treatment is often effective for these conditions,
osteoporosis is one of its most serious complica-
tions. Because of the rapid loss of bone mineral
density (BMD) and increase in fracture risk fol-
lowing the start of corticosteroid treatment, the
early use of preventative measures against corti-
costeroid-induced osteoporosis should be con-
sidered.
Drugs used to treat corticosteroid-induced BMD
loss include calcium, vitamin D, vitamin K, estro-
gen, calcitonin, fluoride, bisphosphonates, and
parathyroid hormone (PTH). These therapies seem
to maintain or increase BMD, and/or may pos-
sibly reduce the incidence of vertebral fractures.
The treatment of osteoporosis is performed
based according to the practice of evidence-based-
medicine (EBM). EBM incorporates information
derived from the highest-quality investigations
with clinical judgment and patient values to
achieve optimal clinical management. A hierarchy
of evidence exists, with meta-analysis repre-
senting the highest level, followed by randomized
controlled trials (RCTs), which have long been
considered the “gold standard” in regards to clini-
cal investigations. This paper discusses the effect
of several drugs on BMD of the lumbar spine and
hip, which are clinically important sites, and the
incidence of vertebral fractures in patients treated
with corticosteroids, considering EBM in terms of
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the results of meta-analyses.
PREVENTION AND TREATMENT OF
CORTICOSTEROID-INDUCED
OSTEOPOROSIS
Pathogenesis of corticosteroid-induced
osteoporosis
Corticosteroid-induced osteoporosis may result
from the direct and indirect actions of cortico-
steroids on bone and calcium homeostasis. Direct
effects include the suppression of intestinal cal-
cium absorption, decreased renal tubular calcium
reabsorption with increased urinary calcium ex-
cretion, and suppressed osteoblast function and
decreased bone formation. Renal and intestinal
losses of calcium result in the development of
secondary hyperparathyroidism, which, in concert
with the stimulation of parathyroid secretion and
an increased sensitivity of bone cells to PTH,
produces an increase in bone resorption and bone
turnover.
1 Several in vitro and ex vivo studies have
indicated that excess corticosteroids promote
apoptosis of osteoblasts and osteocytes, suppress
the production of new osteoblasts and osteoclasts,
and extend the life span of preexisting osteo-
clasts,
2 which play main roles in the pathogenesis
of corticosteroid-induced osteoporosis. Because of
strong correlations between cumulative dose and
loss of BMD, and between daily dose and risk of
fracture, oral corticosteroid therapy using more
than 5 mg (of prednisolone or equivalent) daily is
reported to lead to a reduction in BMD and a
rapid increase in the risk of fracture during the
treatment period.
3,4
Fractures in corticosteroid users have been sug-
gested to occur because of BMD loss. However,
corticosteroid users with fractures in fact have
higher BMD than do in patients with age-related
osteoporosis,
5-7 suggesting a non-BMD-related
mechanism responsible for inducing fractures.
Kanis et al.
8 reported that prior and current ex-
posure to corticosteroids conferred an increased
risk of fracture that was of substantial importance
beyond that explained by measurements of BMD.
Corticosteroid-induced osteoporosis is surmised
to result partially from microarchitectural deterio-
ration predisposing to bone fragility and fractures,
similar to postmenopausal osteoporosis.
Recently, it was reported that the fracture risk
increased rapidly (as early as three months) after
the initiation of corticosteroid therapy, and that it
reversed sharply toward the baseline after its
discontinuation.
9 The most logical explanation for
the rapid onset and offset of fracture risk in corti-
costeroid-induced osteoporosis is suggested to be
osteocyte apoptosis accompanied by a relative
increase in resorption caused by prolongation of
the life span of preexisting osteoclasts.
2 Osteocyte
apoptosis may lead to a deterioration of bone
quality, with a rapid increase in the risk of frac-
ture, because osteocytes play an important role in
the maintenance of bone quality.
2 As far as bone
formation and resorption are concerned, because
the key histological feature of corticosteroid-in-
duced osteoporosis is suppressed bone formation,
manifested as a reduction in trabecular bone
thickness,
10 the mechanisms of bone fragility and
fractures in corticosteroid-induced osteoporosis
may differ from those in postmenopausal oste-
oporosis, in which bone formation and resorption
are increased and trabecular bone connectivity is
reduced.
Prevention and treatment of corticosteroid-
induced osteoporosis
Physicians should primarily avoid the unne-
cessary use of corticosteroids, and should make
every effort to prevent fractures in patients who
are initiating and continuing corticosteroid treat-
ment.
The preservation of the osteocyte network
seems to be an important mechanism by which
bisphosphonates, calcitonin, and estrogen replace-
ment therapy decrease bone fragility and frac-
tures.
11-13 However, because the prevention of
osteoblast apoptosis predictably leads to more
numerous and closely spaced osteocytes,
14 the
prevention of not only osteocyte apoptosis but
also osteoblast apoptosis by treatment is a ration-
ale approach for decreasing bone fragility and
fractures. Although anti-resorptive agents such as
bisphosphonates and anabolic agents such as PTH
have the opposite effect on bone turnover, both
agents have been shown to have potent anti-apop-Jun Iwamoto, et al.
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totic effects on osteoblasts and osteocytes.
13,14
Therefore, both anti-resorptive and anabolic
agents may be the potential candidates for the
treatment of corticosteroid-induced osteoporosis.
Several meta-analysis studies have reported the
efficacy of vitamin D, calcitonin, fluoride, and bis-
phosphonates in patients treated with corticoster-
oids. Amin et al.
15 suggested a hierarchy in effi-
cacy among the agents used for the management
of corticosteroid-induced osteoporosis with re-
spect to their effect on lumbar spine BMD. Their
meta-analysis results indicated that bisphospho-
nates were the most effective of the agents
studied, in comparison with no therapy or treat-
ment with calcium, and were more efficacious
than either vitamin D (both activated vitamin D
and other vitamin D formulations) or calcitonin
(Table 1). These results were similar even when
newer generations of nitrogen-containing bisphos-
phonates were excluded from analysis, and even
when the trial characteristics were divided into
two categories, i.e., prevention and treatment
(treatment initiated within six months of cortico-
steroid therapy; Table 2). The efficacy of fluoride
might be intermediate between that of bisphos-
phonates and that of vitamin D or calcitonin.
15
The combined use of bisphosphonate and vitamin
D has been emphasized, because the efficacy of
bisphosphonates was enhanced when used in
combination with vitamin D. When the outcome
measure of interest was limited to the change in
lumbar spine BMD, bisphosphonates were the
Table 1. Effect of Four Drugs on Lumbar Spine BMD Compared with No Therapy or Treatment with Calcium
- Main Analysis -
Drug
Pooled effect size (95% CI)
( -estimate) β
% Increase in lumbar spine BMD
Vitamin D
Calcitonin
Fluoride
Bisphosphonates
0.46 (0.27, 0.62)
0.51 (0.33, 0.67)
0.64 (0.20, 1.14)
1.03 (0.85, 1.17)
2.0
2.3
2.9
4.6
An effect size obtained from the regression model should be zero if the two drug categories have the same effect on BMD. The
greater the difference in effect on BMD changes between drug categories, the greater the effect size, with an effect size of 0.8
considered to represent a large effect, 0.5 a moderate effect, and 0.2 a small effect.
BMD, bone mineral density. This table was adopted from reference #15.
Table 2. Effect of Four Drugs on Lumbar Spine BMD Compared with No Therapy or Treatment with Calcium
- Sensitivity Analysis -
Pooled effect size (95% CI) ( -estimate) β
Vitamin D Calcitonin Fluoride Bisphosphonates
Activated vitamin D vs. other
vitamin D formulations
0.48 (0.28, 0.75) (active)
0.68 (0.38, 1.01) (others)
Excludes nitrogen-containing
bisphosphonates*
1.03 (0.83, 1.22)
Prevention trials 0.54 (0.20, 0.80) 0.56 (0.30, 0.80) 1.05 (0.66, 1.32)
Treatment trials 0.29 (0.03, 0.57) 0.49 (0.25, 0.68) 0.58 (0.11, 1.00) 1.05 (0.84, 1.27)
* Trials of etidronate and clodronate only.
An effect size obtained from the regression model should be zero if the two drugs categories have the same effect on BMD. The
greater the difference in effect on BMD changes between drug categories, the greater the effect size, with an effect size of 0.8
considered to represent a large effect, 0.5 a moderate effect, and 0.2 a small effect.
BMD, bone mineral density. This table was adopted from reference #15.Corticosteroid-induced Osteoporosis
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most effective of the agents evaluated for man-
aging corticosteroid-induced osteoporosis.
Several meta-analysis/systematic-review studies
have reported the effects of vitamin D, calcitonin,
and bisphosphonates on BMD of the hip as well
as the lumbar spine and the incidence of vertebral
fractures. Homik et al.
16 reported that calcium and
vitamin D preserved BMD at the lumbar spine
with an increase of 2.6% compared with controls
(calcium alone or placebo), but not at the hip, and
did not reduce the incidence of fractures. Richy et
al.
17 also reported that activated vitamin D
(alfacalcidol and calcitriol) maintained lumbar
spine BMD, but did not reduce the incidence of
vertebral fractures. Cranney et al.
18 reported that
calcitonin preserved BMD at the lumbar spine
with an increase of about 3% compared to the
placebo, but did not preserve BMD at the hip, and
did not reduce the incidence of vertebral fractures
in the first year of corticosteroid therapy. The re-
searchers also suggested that the protective effect
of calcitonin on BMD might be greater in patients
who have been taking corticosteroids for more
than three months. Homik et al.
19 analyzed RCTs
of bisphosphonates performed in patients who
had been taking a mean corticosteroid dose of 7.5
mg/day or more, and reported that bisphospho-
nates preserved BMD at the lumbar spine and hip
with an increase of 4.3% and 2.1%, respectively,
compared to the placebo, but did not reduce the
incidence of vertebral fractures. The results of
these reports suggest that vitamin D, calcitonin,
and fluoride stabilize lumbar spine BMD, while
bisphosphonates stabilize both lumbar spine and
hip BMD, with a less certain effect on hip BMD.
The efficacy of vitamin D, calcitonin, fluoride, and
bisphosphonates to reduce the incidence of verte-
bral fractures in patients exposed to corticosteroid
remains to be established.
Efficacy of bisphosphonates for corticosteroid-
induced osteoporosis
According to the results of the meta-analyses,
bisphosphonates were considered to be the most
effective of the agents evaluated for the treatment
of corticosteroid-induced osteoporosis. That is,
treatment with bisphosphonates resulted in a
significant benefit for lumbar spine and femoral
neck BMD in both prevention and treatment
studies. A comparison of the efficacy of etidro-
nate, alendronate, and risedronate based on the
results of RCTs is of great interest.
Adachi et al.
20 performed a pooled data analysis
of the use of intermittent cyclical etidronate for
the prevention and treatment of corticosteroid-
induced BMD loss. They reported that intermit-
tent cyclical etidronate (400 mg/day for two
weeks every three months) was effective in pre-
venting loss of lumbar spine and hip BMD (3.7%
and 1.7% increases compared to placebo) and
reducing the incidence of vertebral fractures in
prevention studies and in slightly increasing lum-
bar spine BMD (4.8-5.4% increase compared to
placebo) in treatment studies. Recently, Sato et
al.
21 examined the effect of intermittent cyclical
etidronate combined with calcium alfacalcidol
on lumbar spine BMD and the incidence of verte-
bral fractures in Japanese men and pre- and
postmenopausal women who were taking >7.5
mg of prednisolone daily for at least 90 days.
Intermittent cyclical etidronate therapy (200 mg/
day for two weeks every three months) combined
with calcium alfacalcidol for three years in-
creased lumbar spine BMD by 4.8%, while cal-
cium alfacalcidol alone increased it by only 0.4
%. Among men and pre- and postmenopausal
women, postmenopausal women showed the
greatest increase in lumbar spine BMD (10.1%).
However, there was no significant reduction in
the incidence of vertebral fractures by intermittent
cyclical etidronate combined with calcium alfa-
calcidol compared to calcium alfacalcidol alone.
Nakayamada et al.
22 also studied the efficacy of
intermittent cyclical etidronate (200 mg/day for
two weeks every three months) combined with
alfacalcidol for lumbar spine and hip BMD in
Japanese men and premenopausal women starting
high-dose corticosteroid treatment (minimum
starting dose 30 mg/day prednisolone or equiva-
lent dose of a methylprednisolone derivative). The
percent changes in lumbar spine and hip BMD
were -10.3% and -2.5%, respectively, in the alfacal-
cidol group, and -4.5% and 2.3%, respectively, in
the intermittent cyclical etidronate combined with
alfacalcidol group. There was no significant dif-
ference in bone turnover markers between the two
groups. Intermittent cyclical etidronate couldJun Iwamoto, et al.
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retard and prevent high-dose corticosteroid-in-
duced BMD loss at the lumbar spine and hip.
Adachi et al.
23 reported on the efficacy of
alendronate for lumbar spine and hip BMD and
the incidence of vertebral fractures in men and
pre- and postmenopausal women continuing to
receive at least 7.5 mg of prednisone or equivalent
daily. Alendronate therapy (5, 10, or 2.5/10 mg
daily) for two years reduced the levels of turnover
markers (urinary N-terminal telopeptides of type
I collagen and serum alkaline phosphatase), in-
creased lumbar spine BMD by 2.8 to 3.9% with a
significant difference from the placebo (0.8% de-
crease), and reduced the incidence of vertebral
fractures (0.7% in the alendronate group versus
6.8% in the placebo group).
Eastell et al.
24 examined the effect of risedronate
on lumbar spine and hip BMD in postmenopausal
women with rheumatoid arthritis requiring
long-term corticosteroid therapy at >2.5 mg/day
prednisolone. Risedronate therapy (2.5 mg daily)
for 97 weeks preserved lumbar spine BMD with
an increase of 1.4% (1.6% decrease in the placebo
group), but did not prevent hip BMD loss com-
pared to the placebo (1.0% and 3.6% decreases in
the risedronate and placebo groups, respectively).
Cohen et al.
25 studied the efficacy of risedronate
for lumbar spine and hip BMD and the incidence
of vertebral fractures in men and pre- and post-
menopausal women who were initiating long-
term corticosteroid treatment. Risedronate therapy
(2.5 or 5 mg daily) for 12 months preserved
lumbar and hip BMD compared to placebo
controls (-0.1 to 0.6% versus -2.8% at the lumbar
spine and -0.4 to 0.8% versus -3.1% at the hip), but
did not reduce the incidence of vertebral fractures.
Reid et al.
26 also studied the efficacy of risedronate
in men and pre- and postmenopausal women
receiving high-dose oral corticosteroid treatment
(prednisone 7.5 mg/day or equivalent) for six
or more months. Risedronate therapy (2.5 or 5 mg
daily) for 12 months increased lumbar BMD with
an increase of 1.9 to 2.9% (0.4% in the placebo
group), preserved hip BMD by -0.2 to 1.8% (-0.3%
in the placebo group), and reduced the incidence
of vertebral fractures by 70% in the two active
treatment groups combined.
For pre- and postmenopausal women as well as
men, where they were included in the studies,
etidronate, alendronate, and risedronate are consi-
dered to have similar benefits for lumbar spine
and hip BMD in patients who are initiating or
receiving corticosteroid treatment. However, the
anti-fracture efficacy in the spine seems to be less
certain, although some RCTs did report efficacy.
According to the results of RCTs, etidronate,
alendronate, and risedronate could be candidates
for preventing vertebral fractures in patients
treated with corticosteroids.
Efficacy of other agents for corticosteroid-
induced osteoporosis
Estrogen
Hall et al.
27 studied the efficacy of hormone
(estrogen) replacement therapy (HRT) for lumbar
spine and hip BMD in postmenopausal women
with rheumatoid arthritis treated with low-dose
corticosteroids. Twenty-four months of HRT
increased lumbar spine and hip BMD by 3.8% and
1.6%, respectively, while calcium supplementation
alone decreased them by 1.2% and 0.6%, sug-
gesting that HRT was effective for preserving
lumbar spine and hip BMD in postmenopausal
women taking low-dose corticosteroids.
Parathyroid hormone
PTH is known to be a potent anabolic agent.
Lane et al.
28 reported changes in BMD after 12
months of daily injections of human PTH (1-34)
[hPTH (1-34)] in postmenopausal women with
osteoporosis treated with corticosteroids and
HRT. Twelve months of PTH estrogen therapy
increased lumbar spine BMD by 11.9% and pre-
served hip BMD (3.3% increase), while estrogen
alone preserved both lumbar spine and hip BMD
(1.1% increase and 1.6% decrease, respectively).
These results suggest that PTH markedly in-
creased lumbar spine BMD and preserved hip
BMD in postmenopausal women with cortico-
steroid-induced osteoporosis who were taking
HRT. The large increase in lumbar spine BMD
due to PTH therapy offers hope that cortico-
steroid-induced BMD loss may be reversed.
Vitamin K2
Vitamin K2 is available in Japan. Vitamin K2 is
a cofactor of γ-carboxylase, which converts glu-Corticosteroid-induced Osteoporosis
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tamic acid residues in osteocalcin to γ-carboxy-
glutamic acid, and is, therefore, essential for the
γ-carboxylation of osetocalcin.
29,30 Because corti-
costeroid therapy decreases serum osteocalcin
levels,
31 vitamin K2 may be effective for the treat-
ment of corticosteroid-induced osteoporosis.
Several studies have reported the efficacy of
vitamin K2 (menatetrenone) for the treatment of
corticosteroid-induced osteoporosis in Japan.
Tanaka and Oshima
32 investigated the risk factors
for vertebral fractures caused by corticosteroid-
induced osteoporosis in 103 patients with collagen
diseases, including rheumatoid arthritis, who
were under treatment with vitamin K2, etidronate
(200 mg/day for two weeks every three months),
or active vitamin D3, or who were not under any
medication to improve bone metabolism for two
years. They demonstrated that the independent
risk factors for the appearance of new vertebral
fractures were age (Odd' ratio 2.03, p=0.008 per
10 years increase), increase in glucocorticoid
dosage (Odd's ratio 6.62, p=0.018), prevalence of
vertebral fractures (Odd's ratio 7.90, p=0.028), low
lumbar spine BMD (Odd's ratio 1.47, p=0.0003 per
5% decrease compared to the young adult mean),
treatment with therapeutic agents, vitamin K2 and
etidronate (Odd's ratio 0.03, p=0.003 and Odd's
ratio 0.02, p=0.002, respectively), and gender
(male) (Odd's ratio 10.9, p=0.011). In particular,
treatment with vitamin K2 and etidronate signifi-
cantly reduced the risk of vertebral fractures
(Odd's ratio 0.03, p=0.003 and Odd's ratio 0.02,
p=0.002, respectively; Fig. 1).
Tanaka and Oshima
33,34 also showed the thera-
peutic effects of etidronate (200 mg/day for two
weeks every three months), vitamin K2 (menate-
trenone), and active vitamin D3 in patients with
corticosteroid-induced osteoporosis, focusing on
the incidence of new vertebral fractures, in 136
patients with collagen diseases other than rheu-
matoid arthritis. During the two-year study
period, new vertebral fractures were observed in
31% of patients in the non-treatment group. The
incidence of vertebral fractures was significantly
reduced in the vitamin K2 and etidronate treat-
ment groups (13% and 11%, respectively), but was
increased in the vitamin D3 treatment group (41
%), suggesting that vitamin K2 as well as etidro-
nate may be efficacious for preventing vertebral
fractures in patients with corticosteroid-induced
osteoporosis.
Although only small numbers of published data
are available for vitamin K2 as a treatment for
corticosteroid-induced osteoporosis, we expect
that the efficacy of vitamin K2 will be demon-
strated in patients treated with corticosteroid who
have a high serum level of undercarboxylated
osteocalcin and/or low serum level of osteocalcin,
taking into consideration the action of vitamin K2
on osteocalcin.
Based on the report that showed the additive
beneficial effects of vitamin K2 to those of a bis-
phosphonate for postmenopausal osteoporosis,
30,35
the efficacy of combined treatment with bispho-
sphonates and vitamin K2 for the incidence of
osteoporotic fractures may be considered for
glucocorticoid-induced osteoporosis.
CONCLUSIONS
A study of meta-analysis representing the
highest level in a hierarchy of evidence showed
that bisphosphonates were the most effective
Fig. 1. Incidence of vertebral fracture after two years of
treatment in patients with corticosteroid-induced osteo-
porosis. The effect of two-year of treatment with vitamin
K2, etidronate (200 mg/day for two weeks every three
months), active vitamin D3, or no treatment on the inci-
dence of vertebral fractures was investigated in cor-
ticosteroid-induced osteoporosis in 103 patients with col-
lagen diseases including rheumatoid arthritis. Treatment
with vitamin K2 and etidronate significantly reduced the
risk of vertebral fractures (Odd’s ratio 0.03, p=0.003 and
Odd’s ratio 0.02, p=0.002, respectively). This figure was
adopted from reference #32.Jun Iwamoto, et al.
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agent in increasing lumbar spine BMD in patients
exposed to corticosteroid, and their efficacy was
enhanced when used in combination with vitamin
D.
15 RCTs representing the second level in a
hierarchy of evidence showed that bisphospho-
nates stabilized BMD not only in the lumbar
spine, but also in the hip, and that PTH markedly
increased lumbar spine BMD. Some RCTs also
demonstrated the anti-fracture effects of etidro-
nate, alendronate, and risedronate in the spine.
Further RCTs of fracture prevention conducted on
a large number of patients and their meta-analysis
are needed to confirm the efficacy of bispho-
sphonates, PTH, or possibly other agents in pre-
venting vertebral and nonvertebral fractures.
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